CEO J. David Warren, who did early research on elamipretide, says the company will target metabolic health and muscle preservation. It's also weighing GLP-1 companion products.
Recap by typeshit. Full story at Yahoo Finance.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
A search result from Polskie Radio on oral semaglutide and weight loss, with no details given beyond the question itself.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Loading…